Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabi-ADP-2: Dabigatran vs Phenprocoumon on Clopidogrel-mediated Platelet Aggregation
NCT01352702Phase 4
Key facts
- Status
- Terminated
- Start
- May 2011
- Primary completion
- May 2014
- Countries
- 1
- Sponsor
- Deutsches Herzzentrum München
- Modality
- Small Molecules
- Drugs
- dabigatran
- Conditions
- Atrial fibrillation (AFib)
01
Overview
Phase 4, randomised, open-label trial of dabigatran in Atrial fibrillation (AFib), sponsored by Deutsches Herzzentrum München. Primary endpoint: ADP induced platelet aggregation at 2 weeks. Started May 2011; status: terminated.
02
Design
- Study design
- RandomizedOpen-label
03
Who it enrols
Patients with atrial fibrillation and an indication for oral anticoagulation (CHA2DS2-VASc score ≥ 1) currently on clopidogrel treatment.
04
Endpoints
Primary
ADP induced platelet aggregation
Beyond the preview
Go deeper on NCT01352702.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01352702.